Navigation Links
Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
Date:8/13/2013

LOUISVILLE, Ky., Aug. 13, 2013 /PRNewswire-iReach/ -- In collaboration with the James Graham Brown Cancer Center at the University of Louisville, LBIdx™ is advancing a breakthrough blood test, the Plasma Thermogram™ (pT). Based on a simple blood draw, researchers at LBIdx™ and the Brown Cancer Center see great promise for the pTtest as a "game-changer" allowing physicians to monitor cancer patients more closely. Monitoring is a critical part of cancer treatment and provides physicians with vital information in the fight against cancer.

LBIdx™ and the Brown Cancer Center are initiating a clinical study that will demonstrate the pT test's capabilities for improved monitoring of melanoma patients at dangerous risk of metastasis and for response to medical treatment. Director Donald Miller M.D., Ph.D. and Deputy Director Jason A. Chesney, M.D., Ph.D., will be co-investigators of the planned study to detect earlier signs of change in disease status. Researchers expect the pTwill provide a unique insight into cancer status leading to improved medical response options, including therapy. Equally important, this test stands to be an earlier indicator or remission or relapse.  In all, the test stands to help answer those age-old questions, "Am I winning my battle with cancer?" and "Is my cancer gone?" 

Current medical practice frequently relies on medical imaging procedures, like CT scans, to monitor melanoma patients. But due to the high dose radiation exposure from each procedure, their use by physicians is limited, which can hinder patient monitoring.  In addition, the FDA is striving to reduce unnecessary radiation exposure from these medical imaging procedures which are the greatest contributors to total radiation exposure within the U.S.

Alfred "Ben" Jenson, Professor of Vaccinology at the James Graham Brown Cancer Center and co-inventor of the pThas been a strong supporter of the pT's cancer monitoring potential.  Ben is also known for his work as co-inventor of the cervical cancer vaccine, Gardasil, and sees potential for the pT as a monitoring tool for a multitude of cancers, including difficult-to-detect oral cancers.

LBIdx™ is a start-up company, focused on the commercialization of pT tests for cancer monitoring and prognosis. It is currently raising funds via a crowd funding campaign allowing the public, who will benefit from such a test, to support this enhanced cancer monitoring effort. Crowd funding is a relatively new concept approved by the U.S. Jobs Act of 2012. Details of their 'Breakthrough in Cancer Detection & Monitoring' campaign can be found on the Indiegogo crowd funding website using the following link, http://igg.me/at/CancerDetectionStudy.

About Louisville Bioscience, Inc.

LBIdx™, headquartered in Louisville, Kentucky, is a start-up company with an exclusive license to the University of Louisville Plasma Thermogram™ (pT) technology and focused on the commercialization of pT tests for cancer monitoring and prognosis.  The novel pT blood test can provide earlier detection of disease, effectively assess status of cancer remission and improve monitoring in response to therapy for numerous cancers including: melanoma, breast, cervical, ovarian and lung cancers. The pT diagnostic platform utilizes Differential Scanning Calorimetry (DSC) to generate a robust temperature-induced melting profile of the major blood proteins. The LBIdx™ core technology was invented by the University of Louisville team of Dr. Jonathan Chaires (James Graham Brown Endowed Chair of Cancer Biophysics), Dr. Nichola Garbett and Dr. Alfred "Ben" Jenson. For more information, please visit www.lbidx.com

Media Contact: Michael Birdsell, LBIdx, 502.414.1243, mbirdsell@lbidx.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE LBIdx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Cloud-Based Investigator Portal from Veeva Systems Speeds Clinical Study Start-Up
2. Structure-Based Drug Design Conference in Boston, Starting June 19 PLUS These 62 Start-ups and Small Companies Will Transform Drug Delivery Technology
3. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
4. Foundation Venture Capital Group Invests In Start-Up Working to Reduce Side Effects of Parkinsons Treatment
5. Helping Start-Ups Avoid Slow-Downs
6. Fuisz Pharma Announces Intent to Divest Strategic Patent for Detection of Opioid Abuse; Seeks Offers for Patent through May 2013
7. $1,000,000 Global B.R.A.I.N. Prize Seeks Applicants
8. American Academy of Pain Medicine Reacts to PROP Petition to the FDA that Seeks to Limit Pain Medications for Legitimate Noncancer Pain Sufferers
9. Searcy Denney Scarola Barnhart & Shipley PA Seeks Damages Caused by Recalled Product
10. Separation Design Group Launches Crowd-Funding Campaign for Worlds Smallest Oxygen Machine
11. Prosum Kicks Off Crowd Funding for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ... ... rise from USD 20 Billion in 2015 to around USD 26 ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
(Date:4/24/2017)... ... 24, 2017 , ... Ridgecrest Herbals makes it a point to lead the ... waste, and support renewable energy. They believe this is a crucial part of their ... for health issues, and maintain that destroying the environment in the pursuit of profit ...
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, ... inhabiting the rarified air of pop and film stardom.(1) Not to be left out ... the smile. Grins now run the gamut from being encrusted with jewels and precious ...
(Date:4/24/2017)... Washington (PRWEB) , ... April 24, 2017 , ... Sean ... OptiGrill, Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which ... perhaps any other marketer in the last 25 years. , Now, due to changes ...
Breaking Medicine News(10 mins):